Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Leukemia, Myelomonocytic, Juvenile 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Etoposide 6Ifosfamide 5Vincristine 4Radiotherapy 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Doxorubicin 4Cyclophosphamide 4Topotecan 2trioctyl phosphine oxide 1indolepropanol phosphate 1imetelstat 1etoposide phosphate 1Vinorelbine 1Vinblastine 1Trabectedin 1Thrombopoietin 1Radiosurgery 1Radiation 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1Microarray Analysis 1Mesna 1MLN 8237 1Irinotecan 1Immunohistochemistry 1Glutamine 1Gene Expression Profiling 1GRN163L peptide 1Electroacupuncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neuroectodermal Tumors, Primitive, Peripheral × GRN163L peptide × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡